Sign inJoin waitlistJoin the waitlist

Keith Ferdinand

Gerald S. Berenson Chair in Preventative Cardiology and Director of Preventative Cardiology · Tulane University School of Medicine

Credentials: · · · · · · ·

History

Tulane University School of Medicine
Present
Tulane University School of Medicine
Present
Tulane University School of Medicine
Present

Louisiana State University Health Sciences Center-New Orleans
1983–1984
Cardiovascular Disease
Howard University Hospital
1980–1983
Internal Medicine
1977–1980
US Public Health Hospital
1976–1977
Howard University College of Medicine
1972–1976
University of New Orleans
1968–1972

Research

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure
New England Journal of Medicine · 2004 · 1,181 citations
Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions
Circulation · 2018 · 1,143 citations
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High…
Hypertension · 2008 · 1,115 citations

ES
Elijah Saunders
17 papers
GB
George Bakris
16 papers
Brent Egan
15 papers
Karol Watson
14 papers
John Flack
13 papers
Carl Pepine
12 papers
Nanette Wenger
12 papers
Tina Reddy
12 papers · 4 as a resident
Clyde Yancy
11 papers
Elizabeth Ofili
11 papers
Jackson Wright
11 papers
Martha Gulati
11 papers

Grants

Church Wellness Coordinator–Led Intervention to Improve Hypertension Control in Communities
National Institute on Minority Health and Health Disparities · R01
PI · $4.5M · Ut Southwestern Medical Center
2022–2027
Community Health Worker-Led Church-Based Intervention for Eliminating Cardiovascular Health Disparities in African Americans
National Heart, Lung, and Blood Institute · UH3
PI · $5.2M · Tulane University of Louisiana
2020–2027

Clinical trials

Text My Hypertension BP Meds NOLA
Principal investigator · Completed
Tulane University
2022
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2026–2030
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031